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Abstract
Objectives: The functionof bone is toprotect the vital organs
of the body. Mechanical strength, especially compressive
strength, plays an important role in fulfilling its function.
Fracture healing depends on several substances, such as
collagen, glucosaminoglycaneandproteoglycan. Chondroitin
sulfate as part of proteoglycane is an important component in
the formation of callus in fracture healing. The aim of this
study is to prove chondroitin sulfate role in supporting frac-
ture healing.
Methods: The in vivo experiment has been performed to
Rattus novergicus which met the inclusion criteria (age
3 months, 200–300 g weight), 18 males of R. norvegicus,
Wistar strain, were divided into three equal groups of six rats
each.After beinganesthetized, fracturationwasperformed in
a sterile manner to get simple fracture. The area of dissection
is in half length of tibial bone and the fracture incision is
about 1 cm. Then it followed by immobilization of the lower
leg bone on one side with a cast. The first group was given
chondroitin sulfate 7mg in 2mL distilled water/200 gweight
for 2 weeks. The second group was given chondroitin sulfate
7 mg in 2 mL distilled water/200 g weight for 4 weeks. The
third group was given distilled water. This research was
focused on treatment of cartilage. The callus position is in
half length of tibial bone.
Results: Therewere significant differences in the increase of
TGF-β, the number of osteoblasts and callus compressive
strength in the groups with chondroitin sulfate treatment for
2 and 4 weeks, compared to the control group (p<0.01).
Conclusions: Administering chondroitin sulfate in a dose
of 7 mg in 2 mL distilled water for 2 and 4 weeks may
increase production of TGF-β, the osteoblast numbers and
the callus compressive strength in fracture healing.
Keywords: callus compressive strength; chondroitin sul-
fate; osteoblast number; Rattus novergicus; TGF-β.
Introduction
The high number of traffic accidents in modern life results in
an increasing incidence of bone fractures, the healing of
which can include complications, such asmalunion, delayed
union and nonunion. Handling fractures cannot succeed
without a full understanding of the cellular mechanisms
of bone healing. There are several factors that can affect the
healing of broken bones onwhich to base a rationalization of
fracture therapy. Thingswhich play important role in fracture
healing consist of local and systemic factors. The local factors
are including degree of local trauma and bone loss, type of
bone affected, degree of immobilization and local pathologic
conditions while the systemic factors are including age,
hormones, local stress and electric currents.
One of the factors influencing healing is indicated by the
presence of collagen type 1, type 2, type 3, glycosaminogly-
cans (GAGs) and proteoglycans deposition. Heparan sulfate,
dermatan sulfate and chondroitin sulfate proteoglycans are
three of the important components of callus formation in the
first 1–2 weeks of fracture healing [1, 2].
Supplementation of oral chondroitin sulfate may
reduce cartilage matrix degradation process components,
especially collagen II, GAGs and other proteoglycans [3, 4].
Karacal N et al. [5] found that chondroitin sulfate plays a
role in accelerating bone healing. In this study, oral
administration of chondroitin sulfate has the same effect on
bone fracture healing and callus formation as local therapy
directly [3, 4]. The healing process of bone, called regener-
ation in fractures, is a complex process, and multifactorial.
Changes that occur in fracture healing are a series of phases
which include the instantaneous phase of the inflammatory
reaction, the development of the osteogenic tissue formation
of callus, and the soft and hard callus remodeling phase [6].
Chondroitin sulfate proteoglycans act as a major
contributor in the early phase of biochemical bone healing.
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Previous research by Liang [7] on the mechanical charac-
teristics, such as modulus of elasticity, compressive
strength and tensile strength to the scaffold, found that the
role of chondroitin sulfate in forming callus strength and
compressive strength in vivo is an unclear mechanism.
Associated with the bone healing, chondroitin sulfate
appeared to accelerate the rate of bony repair [8] but did
not affect the ultimate quantity or quality of bone pro-
duced. In this research, we examine the effect of chon-
droitin sulfate on the bone healing parameter process
including the number of osteoblasts, TGF-β and callus
compressive strength. Osteoblast as bone forming cell play
important role in bone healing process. TGF-β which has
physiological role in the processes of proliferation, differ-
entiation and synthesis of cartilage and bone tissue,
collectively known as the bone healing process. Callus as
bony and cartilaginous material forming a connecting
bridge across a bone fracture during repair is the marker of
bone healing. Within 1–2 weeks after injury, a provisional
callus forms, enveloping the fracture site. Callus
compressive strength could illustrate the condition in
fracture site whether it is leading to bone healing.
Materials and methods
Eighteen rats Rattus novergicus strain Wistar were anesthetized with
ether solution using a hood and titration method. After sedation and
minimal movement of the rats, hair removal was performed in the
lower leg area. After showing the skin, then disinfection with
povidone-iodine and narrowing the field of operation with sterile
Doek. Fracturation was performed in a sterile manner, using sharp
scissors to get a simple fracture, followed by immobilization of the
lower leg bone on one side with a cast. Chondroitin sulfate was
administered in 7 mg/200 g b.w./day via Nasogastric (NG) tube in the
treatment groups. The duration of time for group 1 is 14, 28 days for
group 2 and group 3 was given a placebo in the form of a solution of
0.5%Sodium/NatriumCarboxymethyl Cellulose (CMCNa) via NG tube
with a volume equal to that of the solution of chondroitin sulfate. On
day 28, the rats were anesthetized with ether and 5 cc of blood taken
directly from the heart. Blood samples were placed in EDTA tubes and
sent to the laboratory for examination of physiology levels of TGF-β.
TGF-β levels in the control group and both treatment groups were
measured by the ELISA technique. The lower leg bones containing
bone callus were examined by the anatomical pathology lab, and the
strength of the callus was determined using the Shimadzu Autograf.
Quantifications were performed at 40×magnification to determine the
number of osteoblast cells, the levels of TGF-β in the serum were
measured, and the compressive strength of the callus was measured
with a three-point bending test method using a Shimadzu Autograf on
the incipient fracture healing, and these values were used in a
descriptive analysis. The number of osteoblasts, the levels of TGF-β in
blood serum and the callus compressive strength of each group were
used to perform the statistical test, an F-test statistical analysis by
ANOVA using SPSS. Significance was established based on the value
of p compared with α (5%). All of the research treatments in animal
model has been approved by Ethical Committee of Health Research
Rumah Sakit Umum Daerah Dr Saiful Anwar Malang, East Java,
Indonesia with number of certificate 400/CVVIII/K.3/302/2013.
Results
The bodyweight of rats in all groups showed values greater
than the significance level of p≥0.05 meaning the data are
homogeneous and appropriate for use in the research hy-
potheses by using a one-way ANOVA test.
Levels of TGF-β
TGF-β levels in the control group and both treatment
groups were measured by the ELISA technique. TGF-β at-
tachments levels measured in the control group and the
groups receiving chondroitin sulfate administration for 2
and 4 weeks are shown in Figure 1.
Osteoblast cell count
The number of osteoblasts in the control group and the
treatment groups receiving chondroitin sulfate for 2 and
4weeks were analyzed histologically at 40×magnification.
The number of osteoblasts for the three groups is shown in
Figure 2.
Compressive strength of callus
The compressive strength of callus in the control group and
both treatment groups was measured with a Shimadzu
Autograf. The results for the three groups are shown in
Figure 3.
Figure 1: Diagram of stem histogram levels of TGF-β in the control
and treatment groups.
Description: p<0.01 compared to control group. Remarks: pg/mL
(picogram/mL).
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Discussion
Fracture healing is a complex process consisting of a va-
riety of cellular events in a highly coordinated sequence of
acute inflammation, resolution of inflammation, soft callus
formation (cartilage) and hard callus (woven bone),
angiogenesis, remodeling callus and laminar bone for-
mation to bridge a gap. Woven bone supports forming the
callus that bridges the fracture gap providing stability
during the early healing process. Wovenbone is always
remodeled and replaced by normal lamellar bone, which
provides better mechanical stability [9].
TGF-β is a molecule that is responsible for the quality of
the matrix [10]. Increasing levels of TGF-β in the treatment
groups given chondroitin sulfate for 2 and 4 weeks as
compared to the control group is very significant (p<0.01), as
shown in Figure 1. This indicates that chondroitin sulfate can
modulate the synthesis of TGF-β in the fracture healing pro-
cess. TGF-β is secreted byplatelets in a hematoma in the early
stages by osteoblasts on intramembranous ossification, and
again when the last chondrogenesis chondrocytes and
endochondral ossification takes place [11]. The biological
activity of chondroitin sulfate involves a variety of growth
factors and chemokines, and the function is highly correlated
with the sulfation pattern and characteristics of the poly-
saccharide chain [12]. TGF-β is also bound by chondroitin
sulfate-containing proteoglycans such as biglycan and
decorin. Pathway of chondroitin in stimulating TGF-β release
through the role of decorin and biglycanwhich canmodulate
TGF-β-dependent cellular responses, apparently in a tissue-
specific manner [13].
There is also evidence in the treatment groups given
chondroitin sulfate of increasing osteoblasts, and this is
extremely meaningful compared to the control group
(p<0.01), as shown in Figure 2. This is consistent with the
theory that chondroitin sulfate is involved in the adhesion
of osteoblasts [14, 15]. Chondroitin sulfate is a major
component of cartilage proteoglycans such as aggrecan.
These proteoglycans, decorated with GAG chains, are well
known for their mechanical and biological functions in
articular cartilage [16].
Precursors of osteoblasts are multipotent mesenchymal
stemcells such as bonemarrow stromal cells, chondrocytes,
muscle cells and adipocytes [17, 18]. Osteoblast progenitors
not only of the original mesenchymal stromal progenitors in
the marrow, but also mesenchymal cells attached to the
endothelial lining of blood vessels. Osteoblast precursors
reach bone from the circulation, and have an average life-
span of about 3 weeks. Osteoblasts produce and secrete
matrix proteins fully differentiated from bone. Furthermore
the mineralized matrix will be under the control of osteo-
blasts [17].
Chondroitin sulfate in both treatment groups increased
the compressive strength of callus significantly compared to
the control group (p<0.01) (Figure 3). Chondroitin sulfate can
stimulate proliferation and differentiation of osteoblasts
involved in fracture healing. In addition, there is the possi-
bility that chondroitin sulfate can increase the lifespan of
osteoblasts [18, 19]. Bonematrix is a mixture of fibers (fibrils
of collagen type I) towithstand the force of the pull, andsolid
particles (hydroxyapatite crystals) towithstand compression
[20]. Between the 2nd and 3rd weeks of fracture healing,
callus stiffnesswill increase and angular displacement to the
point of failure decreases. The result of this research is in
accordance with the research of Schneiders W [21] which
showed an increase in compressive strength by 15% by
addition of chondroitin sulfate. Chondroitin sulfate is bind-
ing to the core protein through N- and O-linkages leads to
aggregates of monomers with high molecular weights. The
proteoglycan aggregate showed viscoelastic and hydration
properties [22].
Karaçal N et al. [5] found that chondroitin sulfate plays
a role in accelerating bone healing. Therefore, 3 weeks is
the timewhen the early healing callus formed a bridge, and
Figure 2: Diagram of the stem (histogram). The number of
osteoblasts in the control and treatment groups.
Description: ap<0.01 compared to control group; bp<0.01 compared
to group administered chondroitin sulfate for 2 weeks.
Figure 3: Diagram of the stem (histogram) compressive strength
values of callus in the control and treatment groups.
Description: ap<0.01 compared to control group; bp<0.01 compared
to group treated with chondroitin sulfate for 2 weeks. Description:
Newton (N).
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removed cartilage [6]. In this study, the compressive
strength of the callus increased when chondroitin sulfate
was administered for a longer period of time (4weeks). This
indicates that chondroitin sulfate is capable of improving
the transition of cartilage in the center of the callus into a
bony callus bridge. Thus, chondroitin sulfate can accel-
erate mineralization and bone repair [23].
Chondroitin, better known as chondroitin sulfate, is a
glycosaminoglycan (GAG) composed of a sulfated chain of
branched sugars (N-acetylgalactosamine and glucuronic
acid). It is usually found attached to proteins as part of a
proteoglycan compound. A chondroitin chain can have
over 100 individual sugars that can sulfated in every part of
the variable. Chondroitin sulfate is an important structural
component of cartilage and tissuewith a constituent role in
increasing resistance to stress [24]. Along with glucos-
amine, chondroitin sulfate is widely used as a dietary
supplement to prevent osteoarthritis [25].
The oral dose of chondroitin for use in human
clinical trials is 800–1,200 mg per day. Some other
sources such as shark cartilage, fish and poultry have
been used. Due to chondroitin not being a uniform
substance and naturally arising in many variations and
forms, the composition of each supplement can differ
markedly. This can be caused by supplement manu-
facturers not having to meet the Good Manufacturing
Process (GMP) standards required for human food nor
the standards for the manufacture of pharmaceuticals.
No significant effects of overdoses of chondroitin have
been reported for long-term use. The European League
Against Rheumatism (EULAR) has confirmed that
chondroitin sulfate is one of the safest drugs for osteo-
arthritis [26]. The provision of chondroitin sulfate for 2
or 4 weeks on healing fractures in the treatment groups
was shown to increase the production of TGF-β, the
number of osteoblasts and the compressive strength of
the fracture healing callus.
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